atigotatug/nivolumab (BMS-986489) / BMS - LARVOL DELTA

First in human medical imaging of zirconium-89 labelled anti-fuc-GM1 monoclonal antibody (BMS-986279) in patients with extensive-stage small cell lung cancer (SNMMI 2025) - P2 | ""1801P Expression analysis of Fuc-GM1 ganglioside in first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) with BMS-986012, nivolumab, and carboplatin-etoposide." Annals of Oncology 35 (2024): S1069-S1070. BMS-986279 is suitable for human dosing and proves capable of non-invasive assessment of whole-body fuc-GM1 expression in patients with ES-SCLC. Results suggest tumor penetration of the BMS-986012 labelled monoclonal antibody in lung, liver, and bone lesions."

Clinical • P1 data • Endocrine Cancer • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor

The TIGOS trial: A randomized, double-blind phase 3 trial of atigotatug + nivolumab fixed-dose combination with chemotherapy vs atezolizumab with chemotherapy in patients with 1L extensive-stage small cell lung cancer (ES-SCLC). (ASCO 2025) - P3 | "Clinical Trial Registration Number: NCT06646276 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • P3 data • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

TIGOS-LS, an open-label, randomized study of BMS-986489 vs durvalumab as consolidation therapy following chemoradiotherapy in limited-stage small-cell lung cancer. (ASCO 2025) - P2 | "Clinical Trial Registration Number: NCT06773910 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT"

Clinical • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS) (clinicaltrials.gov) - P2 | N=250 | Recruiting | Sponsor: SCRI Development Innovations, LLC | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

CA245-0001: A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). (clinicaltrials.gov) - P3 | N=530 | Recruiting | Sponsor: Bristol-Myers Squibb | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Bristol-Myers Squibb

New P1 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS) (clinicaltrials.gov) - P2 | N=250 | Not yet recruiting | Sponsor: SCRI Development Innovations, LLC

New P2 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor